Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial

PURPOSE: Ras/MEK/ERK pathway activation is common in oral cavity squamous cell carcinoma (OCSCC). We performed a neoadjuvant (pre-operative) trial to determine biomarker and tumor response of OCSCC to MEK inhibition with trametinib. PATIENTS AND METHODS: Patients with Stage II–IV OCSCC received tram...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Uppaluri, Ravindra, Winkler, Ashley E., Lin, Tianxiang, Law, Jonathan H., Haughey, Bruce H., Nussenbaum, Brian, Paniello, Randal C., Rich, Jason T., Diaz, Jason A., Michel, Loren P., Wildes, Tanya M., Dunn, Gavin P., Zolkind, Paul, Kallogjeri, Dorina, Piccirillo, Jay F., Dehdashti, Farrokh, Siegel, Barry A., Chernock, Rebecca D., Lewis, James S., Adkins, Douglas R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5509449/
https://ncbi.nlm.nih.gov/pubmed/28151720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1469
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak